Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $25.4 million.

  • HCW Biologics' Liabilities and Shareholders Equity fell 418.33% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year decrease of 128.27%. This contributed to the annual value of $30.2 million for FY2024, which is 604.24% up from last year.
  • As of Q3 2025, HCW Biologics' Liabilities and Shareholders Equity stood at $25.4 million, which was down 418.33% from $28.9 million recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Liabilities and Shareholders Equity peaked at $56.4 million during Q3 2021, and registered a low of $13.0 million during Q2 2021.
  • Over the past 5 years, HCW Biologics' median Liabilities and Shareholders Equity value was $33.0 million (recorded in 2023), while the average stood at $36.7 million.
  • In the last 5 years, HCW Biologics' Liabilities and Shareholders Equity soared by 26374.58% in 2022 and then tumbled by 3908.53% in 2023.
  • Over the past 5 years, HCW Biologics' Liabilities and Shareholders Equity (Quarter) stood at $53.5 million in 2021, then decreased by 12.53% to $46.8 million in 2022, then crashed by 39.09% to $28.5 million in 2023, then rose by 6.04% to $30.2 million in 2024, then dropped by 15.85% to $25.4 million in 2025.
  • Its last three reported values are $25.4 million in Q3 2025, $28.9 million for Q2 2025, and $26.3 million during Q1 2025.